-
-
-
-
-
-
-
Pfizer reafffirms 2026 guidance after CFO transition announcement
-
-
-
-
-
-
-
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
-
-
-
-
-
-
-
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
-
-
-
-
-
-
-
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
-
-
-
-
-
-
-
Pfizer's ELREXFIO meets primary endpoint in multiple myeloma trial
-
-
-
-
-
-
-
FDA grants priority review to Astellas-Pfizer cancer drug application
-
-
-
-
-
-
-
Pfizer's TALZENNA combination shows progress against prostate cancer
-
1,202,194 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

